Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Research in brief: Coagulopathy in COVID-19: Determining and managing thrombotic risk in COVID-19 infection

Rajan S Pooni
Download PDF
DOI: https://doi.org/10.7861/clinmed.rib.20.4.2
Clin Med July 2020
Rajan S Pooni
ANewham University Hospital, London, UK
Roles: internal medicine trainee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Background

Summary of Stoneham SS, Milne KM, Nuttall E et al. Thrombotic risk in COVID-19: a case series and case-control study. Clin Med 2020;20:e76–81.

The observation of an underlying hypercoagulable state in COVID-19 infection has raised questions about how best to determine and manage its underlying risk in preventing and treating venous thromboembolism (VTE).1 The high incidence of VTE in COVID-19 is comparable to other viral pneumonias (notably severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS-CoV)), particularly in patients with prolonged disease or in multiorgan failure.2,3 However, the pathogenesis of hypercoagulability remains unclear.4 Current hypotheses include endothelial injury as a direct effect of virus invasion and sepsis-induced coagulopathy (SIC) manifesting as a disseminated intravascular coagulopathy (DIC)-like syndrome, with thrombosis predominating rather than bleeding.1,3,5

Existing literature has focused almost solely on VTE in COVID-19 infection in the context of intensive care or high-dependency settings. In this clinical summary we review the association between COVID-19 infection and thrombotic events in ward-based patients admitted to Brighton and Sussex University Hospitals NHS Trust from 20 March 2020 to 09 April 2020.

Study findings

Two-hundred and seventy-four patients with either confirmed (PCR positive) or probable (radiographic evidence) of COVID-19 underwent biochemical evaluation of laboratory markers, specifically their D-dimer values, to determine whether there was any statistical difference between the group of patients with confirmed VTE (cases) compared those patients without VTE (controls).

Of the 274 patients, 21 (7.7%) were diagnosed with VTE (pulmonary embolism or deep vein thrombosis) and unsurprisingly this group of patients demonstrated higher (>0.5 μg/mL) D-dimer values (4.1; p<0.001) when compared to the control group. Of note is the confirmation that patients in the control group also demonstrated the hypercoagulable state, with an average D-dimer of 1.2. With such a high risk of VTE observed in the control group, despite thromboprophylaxis, perhaps there is a role for D-dimer level-guided thromboprophylaxis regimens.6,7

Perhaps most interestingly is the identification of a cohort of patients who were refractory to treatment with standard anticoagulation. Three such patients with confirmed VTE demonstrated subtherapeutic anti-factor Xa levels or activated partial thromboplastin time (APTT) ratio despite administration of weight-based low molecular weight or unfractionated heparin. All three patients exhibited very high levels of factor VIII and von Willebrand factor that may represent both a marker of SARS-CoV-2 induced endothelial damage and an important mechanistic cause of COVID-19 related thrombosis.

What does this mean in practice?

  • Hypercoagulability is a recognised state in COVID-19 infection. Markedly elevated D-dimer values should increase clinical suspicion VTE and may warrant further investigation.

  • Further haematological investigation should be considered in patients with confirmed VTE, particularly if no clinical improvement is observed and clot progression is suspected.

  • Anti-factor Xa levels and APTT ratios are a good way to determine the efficacy of weight-based low molecular weight and unfractionated heparin regimens in patients with confirmed VTE.

  • © Royal College of Physicians 2020. All rights reserved.

References

  1. ↵
    1. The Lancet Haematology
    . COVID-19 coagulopathy: an evolving story. Lancet Haematol 2020;7:e425.
    OpenUrl
  2. ↵
    1. Moores LK
    , Tritschler T, Brosnahan S, et al. Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report. Chest 2020:S0012-3692(20)31625-1 [Epub ahead of print].
  3. ↵
    1. Connors JM
    , Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135:2033–40.
    OpenUrlPubMed
  4. ↵
    1. Iba T
    , Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost 2020 [Epub ahead of print].
  5. ↵
    1. Panigada M
    , Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020 [Epub ahead of print].
  6. ↵
    1. Artifoni M
    , Danic G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis 2020;50:211–6.
    OpenUrl
  7. ↵
    1. Wang T
    , Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol 2020;7:e362–3.
    OpenUrl
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Research in brief: Coagulopathy in COVID-19: Determining and managing thrombotic risk in COVID-19 infection
Rajan S Pooni
Clinical Medicine Jul 2020, 20 (4) e59; DOI: 10.7861/clinmed.rib.20.4.2

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research in brief: Coagulopathy in COVID-19: Determining and managing thrombotic risk in COVID-19 infection
Rajan S Pooni
Clinical Medicine Jul 2020, 20 (4) e59; DOI: 10.7861/clinmed.rib.20.4.2
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Background
    • Study findings
    • What does this mean in practice?
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Higher heparin dosages reduce thromboembolic complications in patients with COVID-19 pneumonia
  • Google Scholar

More in this TOC Section

  • Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction
  • Research in brief: Effective pharmacotherapy for the management of obesity
  • Research in brief: Colchicine for chronic coronary disease: a recent randomised controlled trial
Show more Research in brief

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians